QCQicheng Chen

Qicheng Chen

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Qicheng Chen has a total of 13 co-authors. Here are the top co-authors by number of shared publications:

  • Haiping Zeng

    Department of Gastrointestinal Surgery, Guangdong Provincial Hospital of Chinese Medicine, Guangzhou, China

    1 shared publication
  • Jie Wang

    The Second Clinical College, Guangzhou University of Traditional Chinese Medicine, Guangzhou 510006, China

    1 shared publication
  • Junming He

    Department of Hepatobiliary Surgery, The Second AffiliatedHospital of Guangzhou University of Chinese Medicine, Guangzhou, 510120, China

    1 shared publication
  • Lixing Cao

    Department of Perioperative Research Centre of Chinese Medicine, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, 510120, China

    1 shared publication
  • Lixing Cao

    The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, China

    1 shared publication
  • Tao Wang

    The Second Clinical Medical College of Guangzhou University of Traditional Chinese Medicine, Guangzhou 510000, China

    1 shared publication

Latest Publications

  • Wuda Granule Modulates miR-635-3p Expression to Downregulate CCL11 and Restrain Colorectal Cancer Proliferation

    by Zhi Jiang, Xing Li, Qicheng Chen, Zhiqiang Chen, Junming He, Lixing Cao

    Introduction: Colorectal cancer (CRC) is a leading cause of cancer-related deaths globally, with a rising incidence in developing regions. The Traditional Chinese Medicine formulation Wuda granule (WDG) shows potential in treating gastrointestinal motility disorders, but its role and molecular mechanisms in CRC remain unclear. Methods: miRNA microarray and quantitative real-time PCR (qRT-PCR) analyses were used to assess miR-656-3p expression in smooth muscle cells from five CRC patients and colorectal cancer cell lines following WDG treatment. Functional assays, including colony formation and CCK-8 proliferation tests, evaluated the effects of miR-656-3p overexpression on CRC cell proliferation. Bioinformatics prediction, gene expression analysis, Western blotting, immunofluorescence, and dual- luciferase reporter assays were conducted to identify and validate CCL11 as a direct target of miR-656-3p. The impact of WDG treatment on CCL11 expression was examined with and without miR-656-3p inhibition. Additionally, the role of CCL11 overexpression in reversing WDG-induced effects was investigated. Results: WDG treatment significantly upregulated miR-656-3p expression in smooth muscle cells of CRC patients and colorectal cancer cell lines. Overexpression of miR-656-3p markedly inhibited CRC cell proliferation. CCL11 was identified as a direct target of miR-656-3p, with WDG treatment reducing CCL11 expression at both mRNA and protein levels. Inhibition of miR-656-3p reversed this effect, while overexpression of CCL11 rescued the proliferative capacity of CRC cells suppressed by WDG treatment. Discussion: Our findings identified miR-656-3p as a tumor suppressor in colorectal cancer through its direct targeting of CCL11. We further demonstrated that Wuda granule exerts anti-tumor effects by upregulating miR-656-3p, revealing a novel therapeutic mechanism. This study provides new insights into miRNA-based therapies for CRC, highlighting the clinical potential of targeting the miR656-3p/CCL11 axis. Conclusion: Wuda granule inhibits colorectal cancer growth through a miR-656-3p-mediated suppression of CCL11, validating the miR-656-3p/CCL11 axis as a potential therapeutic target for CRC management.

  • Open Access

    Metabolomics Analysis of Laparoscopic Surgery Combined with Wuda Granule to Promote Rapid Recovery of Patients with Colorectal Cancer Using UPLC/Q‐TOF‐MS/MS

    by Tao Wang, Yihua Xu, Qicheng Chen, Weilin Zheng, Jie Wang, Haiping Zeng, Yuyan Wu, Lixing Cao, Zhiqiang Chen

    Surgery is the primary curative treatment for patients with nonmetastasized colorectal cancer (CRC). Rate of complications, morbidity, mortality, and overall survival of patients with CRC are factors associated with speed of recovery following surgery. Wuda granule (WD) is a traditional Chinese medicine (TCM) prescription used to promote rapid recovery after surgery. However, the specific mechanism of action of WD has not been characterized. Our study included 60 patients with clear histopathological evidence of colon or rectal cancer who underwent CRC laparoscopic surgery and 30 healthy individuals. Serum biochemistry and clinical evaluation of gastrointestinal function showed that WD could improve the nutritional status and gastrointestinal function and reduce the level of inflammation of patients with CRC following laparoscopic surgery. In addition, we used UPLC/Q‐TOF‐MS/MS‐based metabolomics analysis to determine the mechanism of WD‐related rapid recovery following laparoscopic surgery in patients with CRC. Twenty metabolites associated with arachidonic acid, alanine, aspartate and glutamate, α‐linolenic acid, pyruvate, histidine, and glycerophospholipids were identified. The results suggested that the therapeutic mechanism of laparoscopic surgery combined with WD may be related to regulation of nutritional status, inflammation, immune function, energy, and gastrointestinal function in patients with CRC. This study also highlighted the ability of TCM compounds to interact with multiple targets to induce synergistic effects. This study may result in further studies of WD as a therapeutic agent to promote recovery following surgical resection of CRC tumors.